Strongbridge Biopharma plc Profit Margin

As of the most recent data (June 2021), SBBP shows a profit margin of -1.16%. That compares with -2.05% in the prior-year period — up 43.6% year over year. That is below the Healthcare sector average of 15.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBBP's profit margin is now -1.16% (was -2.05%) — a 43.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Strongbridge Biopharma plc is outperforming or lagging.

The Healthcare sector average profit margin is about 15.58%. Strongbridge Biopharma plc is at -1.16%, which is lower that average. That is roughly 842.2% below the sector mean. Use the comparison chart on this page to see how SBBP stacks up against individual peers as well.

That compares with -2.05% in the prior-year period — up 43.6% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Strongbridge Biopharma plc with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Strongbridge Biopharma plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -1.16%) with ownership activity and broader fundamentals.